EFFECTS OF TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB ON PATIENT REPORTED OUTCOMES IN A PHASE 3 STUDY OF ACTIVE RHEUMATOID ARTHRITIS

被引：1
|
作者：
van Vollenhoven, R. F. [1 ]
Wallenstein, G. [2 ]
Lee, E. B. [3 ]
Fleischmann, R. [4 ]
Zwillich, S. H. [2 ]
Gruben, D. [2 ]
Koncz, T. [5 ]
Bradley, J. [2 ]
Wilkinson, B. [2 ]
Strand, V. [6 ]
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Pfizer Inc, Groton, CT USA
[3] Seoul Natl Univ, Seoul, South Korea
[4] Metroplex Clin Res Ctr, Dallas, TX USA
[5] Pfizer Inc, New York, NY USA
[6] Stanford Univ, Palo Alto, CA 94304 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
D O I：
10.1136/annrheumdis-2012-eular.2116
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [31] IMPROVEMENTS IN DISEASE ACTIVITY SCORE BY BASELINE STATUS: POOLED ANALYSIS OF FIVE PHASE 3 STUDIES WITH TOFACITINIB (CP-690,550) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
    Fleischmann, R. M.
    Krishnaswami, S.
    Gruben, D.
    Zwillich, S. H.
    Mebus, C.
    Bradley, J. D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 207 - 207
  • [32] Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
    Burmester, Gerd R.
    Blanco, Ricardo
    Charles-Schoeman, Christina
    Wollenhaupt, Juergen
    Zerbini, Cristiano
    Benda, Birgitta
    Gruben, David
    Wallenstein, Gene
    Krishnaswami, Sriram
    Zwillich, Samuel H.
    Koncz, Tamas
    Soma, Koshika
    Bradley, John
    Mebus, Charles
    [J]. LANCET, 2013, 381 (9865): : 451 - 460
  • [33] Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
    Strand, Vibeke
    van Vollenhoven, Ronald F.
    Lee, Eun Bong
    Fleischmann, Roy
    Zwillich, Samuel H.
    Gruben, David
    Koncz, Tamas
    Wilkinson, Bethanie
    Wallenstein, Gene
    [J]. RHEUMATOLOGY, 2016, 55 (06) : 1031 - 1041
  • [34] A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
    Kremer, Joel M.
    Cohen, Stanley
    Wilkinson, Bethanie E.
    Connell, Carol A.
    French, Jonathan L.
    Gomez-Reino, Juan
    Gruben, David
    Kanik, Keith S.
    Krishnaswami, Sriram
    Pascual-Ramos, Virginia
    Wallenstein, Gene
    Zwillich, Samuel H.
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (04): : 970 - 981
  • [35] 6 weeks of treatment of active rheumatoid arthritis with an orally active inhibitor of JANUS kinase 3, cp-690,550, is associated with dose-dependent increases in remission rates and improvement in the CDAI and SDAI
    Breedveld, F. C.
    Bloom, B. J.
    Coombs, J.
    Fletcher, M. P.
    Gruben, D.
    Kremer, J. M.
    Krishnaswami, S.
    Burgos-Vargas, R.
    Zerbini, C.
    Wilkinson, B.
    Zwillich, S. H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 441 - 441
  • [36] Co-administration of an oral JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis
    Wilkinson, B.
    Chow, V.
    LaBadie, R.
    Zwillich, S. H.
    Cohen, S.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S297 - S297
  • [37] Improvement in psoriatic lesions during a 14-day trial of CP-690,550 (CP), an orally active inhibitor of janus kinase 3 (jak3)
    Wilkinson, B.
    Gaweco, A.
    Changelian, P.
    Boy, M.
    Wang, C.
    Chow, V.
    Chan, G.
    Herron, J.
    Zwillich, S.
    Krueger, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 155 - 155
  • [38] Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, significantly improves the symptoms of moderate to severe psoriasis with early onset of efficacy
    Harness, Jane
    Menter, Alan
    Tan, Huaming
    Papp, Kim
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB149 - AB149
  • [39] Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, consistently improves the clinical signs of moderate to severe psoriasis in different body regions
    Papp, Kim
    Menter, Alan
    Tan, Huaming
    Harness, Jane
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB153 - AB153
  • [40] Effects Of Tofacitinib, An Oral Janus Kinase Inhibitor, On Work Limitations In Patients With Rheumatoid Arthritis
    Strand, Vibeke
    Kanik, Keith S.
    Connell, Carol
    Wilkinson, Bethanie
    Gruben, David
    Wallenstein, Gene
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S1002 - S1002
12345